Co-Administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human Α-Galactosidase a Tissue Uptake and Improves Substrate Reduction in Fabry Mice

Molecular Therapy - United States
doi 10.1038/mt.2011.271
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Fabry Disease: Effective Tissue Substrate Depletion Following Enzyme Replacement in Α-Galactosidase a Deficient Mice. • 607

Pediatric Research
Child HealthPediatricsPerinatology
1997English

Distribution of -Galactosidase a in Normal Human Kidney and Renal Accumulation and Distribution of Recombinant -Galactosidase a in Fabry Mice

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2007English

Receptor-Mediated Endocytosis of Α-Galactosidase a in Human Podocytes in Fabry Disease

PLoS ONE
Multidisciplinary
2011English

Adipocytes Participate in Storage in Α-Galactosidase Deficiency (Fabry Disease)

Journal of Inherited Metabolic Disease
Genetics
2010English

Prediction of Response of Mutated Alpha-Galactosidase a to a Pharmacological Chaperone

Pharmacogenetics and Genomics
Molecular MedicineGeneticsMolecular Biology
2008English

Fabry Disease: Twenty Novel Α-Galactosidase a Mutations Causing the Classical Phenotype

Journal of Human Genetics
Genetics
2001English

Impact of Cysteine Variants on the Structure, Activity, and Stability of Recombinant Human Α-Galactosidase A

Protein Science
BiochemistryMedicineMolecular Biology
2015English

Strong Increase of Leukocyte Apha‐galactosidase a Activity in Two Male Patients With Fabry Disease Following Oral Chaperone Therapy

Molecular genetics & genomic medicine
GeneticsMolecular Biology
2019English

Monoclonal Antibody Po66 Uptake by Human Lung Tumours Implanted in Nude Mice: Effect of Co-Administration With Doxorubicin

British Journal of Cancer
Cancer ResearchOncology
1995English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy